All In Biotech

Drug Trial Radar · NCT05540288

NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

Last checked: Nov 20, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 266 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

266

Planned (sponsor's estimate)

Start

Mar 31, 2023

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Nantes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Behavioural addictions (BAs) \[gambling disorder (GD), food addiction (FA), sexual addiction (SA)\] may lead to disastrous consequences. They are often associated with other addictive or psychiatric disorders, and high rates of suicide attempts. Epidemiological studies report prevalence reaching 2.7% for GD, 5% for SA, and up to 7.9% for FA. Many similarities have been highlighted between BAs, as well as with substance use disorders. One core clinical similarity between those disorders is craving (uncontrollable urge to engage in rewarding behaviours), which has been consistently associated with diminished control over the behaviour and relapse. At present, no pharmacological treatment has been approved for BAs, but several medications have been tested. Among them, two opioid receptor antagonists - naltrexone and nalmefene - appear the most promising. By decreasing dopamine neurotransmission in the reward circuitry, they reduce both excitement for rewarding behaviours and craving. Compared to naltrexone, nalmefene seems to have a better safety. To date, no study investigated the efficacy of nalmefene as a pan-addiction treatment for BAs. Two clinical trials have demonstrated its efficacy for the treatment of GD, but no clinical trial was conducted for FA and SA. The investigators hypothesise that nalmefene (36 mg/d), compared to a placebo, can have a therapeutic effect as an add-on to usual treatment for decreasing craving in several BAs.

Conditions

  • Behavioural Addiction

Interventions

  • NalmefeneDrug

    Week 1: 18 mg/d Week 2: 1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d 2. In the presence of grade 3 ARs, 18 mg/d 3. In the presence of grade 4 ARs, treatment will be stopped immediately. Week 3 to week 5: 1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage 2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped. 3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage 4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d 5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.

  • PlaceboDrug

    Week 1: 1 tablet/d Week 2: 1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d 2. In the presence of grade 3 ARs, 1 tablet/d 3. In the presence of grade 4 ARs, the treatment will be stopped immediately. Week 3 to week 5: 1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage 2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped. 3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage 4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d 5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Variation of averaged intensity of craving episodes between start and end of treatment.Time frame: 5 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Besançon

    Besançon, France · Not yet recruiting

  • CHU de Bordeaux

    Bordeaux, France · Recruiting

  • CHRU de Brest

    Brest, France · Recruiting

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France · Recruiting

  • CHU de Dijon

    Dijon, France · Not yet recruiting

  • CH de La Rochelle

    La Rochelle, France · Recruiting

  • Hospices Civils de Lyon

    Lyon, France · Recruiting

  • CHU de Montpellier

    Montpellier, France · Not yet recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • CHU de Nîmes

    Nîmes, France · Recruiting

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, France · Recruiting

  • CHRU de Tours

    Tours, France · Recruiting

  • Hôpital Paul Brousse

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.